Portfolio
Strategy
Team
News
Careers
Contact
Investor Login
Portfolio
Strategy
Team
News
Careers
Contact
Artiva Biotherapeutics Announces First Patient Dosed in Phase 1 Trial of AlloNK® Cell Therapy Candidate in Lupus Nephritis
Read Article
News
2024
2023
Archive
Search news articles
November 14, 2022
Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting
November 14, 2022
Rallybio Announces Pricing of $50 Million Public Offering
November 10, 2022
Rallybio Announces Proposed Public Offering
November 8, 2022
CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions
November 7, 2022
CinCor Pharma Announces Publication in the New England Journal of Medicine of Phase 2 BrigHtn Data on Selective Aldosterone Synthase Inhibitor Baxdrostat in Treatment-Resistant Hypertension
November 7, 2022
CinCor Pharma Appoints Michael W. Kalb, Executive Vice President and Chief Financial Officer
November 7, 2022
Pear Therapeutics Presents Real-world Data Showing Reduction in Healthcare Resource Utilization and Associated Costs in Adults Using Somryst® at ISPOR Europe
November 7, 2022
Nouscom’s Personalized Neoantigen Cancer Immunotherapy NOUS-PEV Demonstrates Promising Safety, Immunogenicity and Anti-tumor Activity in Solid Tumors
November 7, 2022
Leading Fertility Company TMRW Life Sciences Receives FDA 510(k) Clearance for Next-Generation Technology to Safely Manage and Store Frozen Eggs and Embryos
November 7, 2022
Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5
« Previous Page
1
2
3
4
5
6
…
103